0
Pulmonary Vascular Disease |

Clinical Characterization and Survival in Patients With Pulmonary Hypertension

Safiye Özkan, PhD
Author and Funding Information

Istanbul University Florence Nightingale Faculty of Nursing, Istanbul, Turkey


Chest. 2013;144(4_MeetingAbstracts):851A. doi:10.1378/chest.1667449
Text Size: A A A
Published online

Abstract

SESSION TITLE: DVT/PE/Pulmonary Hypertension Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: To assess clinical characteristics and survival of persons diagnosed with pulmonary hypertension (PAH) between 2005 and 2011 years.

METHODS: From the Yedikule Chest Diseases and Thoracic Surgery Training and Investigation Hospital database between 2005-2011 years 18 PAH patients were identified. In the stage of diagnosis, blood count, biochemistry, radiology, pulmonary function tests, ECHO, ProBnP, cardiopulmonary hemodynamics retrospectively analyzed. According to New York Heart Association Functional Classification (NYHA) and 6-min walk distance (6MWD) the functional assessment of participation were retrospectively analyzed. Data analysis performed using number, percentage, mean, standart deviation, minimum, maximum. Survival analysis was performed using the Kaplan-Meier method.

RESULTS: The mean ages of patients with PAH were 56.62±14,97. 12 (66.7%) were female. The estimated mean survival was 2.83±0.13 years. One of patients had a family history. 7 (38.9%) were diagnosed with IPAH, 6 (33.3%) with scleroderma and PAH, 3(16.7%) with chronic thromboembolic pulmonary hypertension (CTEPH), 1 (5.6%) with idiopathic pulmonary fibrosis (IPF) and PAH, 1 (5.6%) with PAH. The mean ProBnP of patients were 575.9±504. Eight patients were given calcum channel blokers, eight patients were given bosentan and two patients were given bosentan and inhaler iloprost. Eight patients died during treatment. (One patient whiles the planning of surgical treatment, the three patients had the scleroderma and PAH, the two patients had the IPAH, and the one patient had the IPF and PAH).

CONCLUSIONS: Mortality in PAH is largely associated with hemodynamic variables that assess right ventricular function. A relatively low specificity to predict survival in our PAH population. In the diagnosis and following phase of collagen tissue illness and the chronic thromboembolism can be seen PAH.

CLINICAL IMPLICATIONS: Multicenter trial is needed to evaluate the survival and prognostic factor in all patients with PAH in Turkey. In conclusion, in the diagnosis and following phase of collagen tissue illness and the chronic thromboembolism can be seen PAH. Patients with PAH have poor survival expectancy and in this limited study with a small number of patients.

DISCLOSURE: The following authors have nothing to disclose: Safiye Özkan

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543